Summary
This article is important as it highlights the many benefits of the Niacin drugs. It describes how MK-0524 may significantly increase adherence as it reduces the side effect of flushing.
This article describes preliminary trials with the new formulation clearly showing a reduction in the side effect of flushing.
The article also reiterates the many benefits of Niacin drugs on all parts of the lipid profile: lowering LDL, raising HDL, and lowering Triglyceride.
Analysis
1. Results of recent research and subsequent guidelines now require more aggressive treatment of dyslipidemia. To reach the goal, we need higher doses of medications and combination therapy. Use of Niacin medications have been limited by flushing. MK-0524 may significantly reduce flushing and allow increased use of Niacin.
2. Research and guidelines have also focused on treatment of low HDL. Low HDL is clearly a risk factor for coronary heart disease and most likely an independent risk factor. Niacin drugs have been shown to raise HDL. If MK-0524 allows greater tolerance for these drugs I will be able to expand my usage.
3. Research suggests that Lipoprotein (a) is associated with risk for cardiovascular disease. It is still unclear whether treating high Lp(a) will result in morbidity and mortality benefits. I generally measure Lp(a) and if elevated, I use a Niacin drug as part of my treatment plan. Once again, a better tolerated formulation will be helpful.
4. Niacin drugs favorably influence all lipid fractions: LDL, HDL, and Triglycerides. The drugs can be used alone or in combination with a statin.
5. Niacin drugs have not caused muscle soreness or elevations in CK, also a benefit.
